A Comparison of Two Anti-HIV Treatment Plans
HIV Infections
About this trial
This is an observational trial for HIV Infections focused on measuring HIV-1, Drug Administration Schedule, Drug Resistance, Microbial, Disease Progression, Genotype, Phenotype, Drug Resistance, Multiple, Anti-HIV Agents, Treatment Experienced
Eligibility Criteria
Inclusion Criteria Patients may be eligible if they: Have proof of MDR virus from a blood test. Have a viral load above 5,000 copies/ml from the same blood sample showing MDR virus. Intend to start a new anti-HIV treatment around the time of the study. Have been on a stable anti-HIV treatment between 14 days prior to the blood test mentioned above and when they are randomly assigned to a treatment. Are at least 13 years old (consent of parent or guardian required if under 18). (This protocol has been changed to reflect new criteria.) Exclusion Criteria Patients will not be eligible if they: Have received a vaccine or had an illness that might affect viral load within 14 days before the blood test showing MDR virus. Have received IL-2 within 4 months of the above-mentioned blood test or plan to take IL-2 during the study. Have an opportunistic (AIDS-related) infection requiring treatment. Are pregnant or breast-feeding. Are currently participating in CPCRA 057 (PIP study).
Sites / Locations
- Community Consortium / UCSF
- Lawrence Goldyn, MD
- Denver CPCRA / Denver Public Hlth
- Univ Hosp Infectious Disease
- Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit
- Washington Reg AIDS Prog / Dept of Infect Dis
- AIDS Research Alliance - Chicago
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
- Our Lady of the Lake Regional Med Ctr
- Wayne State Univ - WSU/DMC / Univ Hlth Ctr
- Henry Ford Hosp
- Southern New Jersey AIDS Clinical Trials
- North Jersey Community Research Initiative
- Bronx-Lebanon Hosp Ctr
- Harlem AIDS Treatment Grp / Harlem Hosp Ctr
- The Research and Education Group
- Philadelphia FIGHT
- Montrose Clinic
- Houston Veterans Administration Med Ctr
- Univ TX Health Science Ctr
- Richmond AIDS Consortium / Div of Infect Diseases